(Q38559125)

4 September 2017

1 reference

title

Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles (English)

1 reference

4 September 2017

O'Hagan DT

1

1 reference

4 September 2017

Ott GS

series ordinal

2

1 reference

4 September 2017

Van Nest G

series ordinal

3

1 reference

4 September 2017

publication date

1 February 1997

1 reference

Trends in Molecular Medicine

4 September 2017

published in

1 reference

4 September 2017

volume

3

1 reference

4 September 2017

issue

2

1 reference

4 September 2017

page(s)

69-75

1 reference

Antibody and cytotoxic T-cell responses to soluble hepatitis B virus (HBV) S antigen in mice: implication for the pathogenesis of HBV-induced hepatitis.

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910058-7

7 January 2021

Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910058-7

7 January 2021

Immunological adjuvants: a role for liposomes

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910058-7

7 January 2021

Immunologic aspects of liposomes: presentation and processing of liposomal protein and phospholipid antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910058-7

7 January 2021

Adjuvant activity of iscoms; effect of ratio and co-incorporation of antigen and adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910058-7

7 January 2021

An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910058-7

7 January 2021

Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59.

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910058-7

7 January 2021

Advances in influenza virus vaccine research

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910058-7

7 January 2021

A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected]

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910058-7

7 January 2021

Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910058-7

7 January 2021

Mucosal antibodies to human cytomegalovirus glycoprotein B occur following both natural infection and immunization with human cytomegalovirus vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910058-7

7 January 2021

Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910058-7

7 January 2021

Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910058-7

7 January 2021

Controlled release microparticles for vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910058-7

7 January 2021

Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910058-7

7 January 2021

Orally administered microencapsulated Bordetella pertussis fimbriae protect mice from B. pertussis respiratory infection

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910058-7

7 January 2021

Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910058-7

7 January 2021

Protection against vaginal SIV transmission with microencapsulated vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910058-7

7 January 2021

Mucosal IgA response to rectally administered antigen formulated in IgA-coated liposomes

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910058-7

7 January 2021

Probing the structure-activity relationship of Escherichia coli LT-A by site-directed mutagenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910058-7

7 January 2021

Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910058-7

7 January 2021

A month-long effect from a single injection of microencapsulated human growth hormone

1 reference

https://api.crossref.org/works/10.1016%2FS1357-4310%2896%2910058-7

7 January 2021

10.1016/S1357-4310(96)10058-7

Identifiers

DOI

1 reference

4 September 2017

1 reference